35 results about "Phosphatidylethanol" patented technology

The present invention relates to a quercetin long-acting liposome powder injection and its preparation method. Said powder injection is formed from quercetin, polyethylene glycol-ethanolamine phosphoglycerides, lecithin, cholesterol and excipient. Said invention also provides the concrete steps of its preparation method.

A freeze-dried powder of honokiol liposome for preparing the medicines to treat lung cancer and mammary cancer is proportionally prepared from honokiol, polyethanediol-phosphatidylethanolamine, lecithin and cholesterol. It has high synergistic and sensitizing action when it is applied in conjunction with chemicotherapeutic medicine.

The invention discloses a propranolol hydrochloride lipidosome gel, which is prepared by the following bulk drugs and auxiliary materials by weight percent: 0.012-0.075% of propranolol hydrochloride, 0.037-0.150% of phosphatidyl ethanolamine, 0.012-0.075% of cholesterol, 2.5-5% of triethanolamine, 1-2% of carbopol, and the balance of water. According to the propranolol hydrochloride lipidosome gel, during the preparation, the lipidosome is uniformly dispersed in the gel, so that the stability of the lipidosome is improved; the water-soluble gel carbopol has excellent biocompatibility, can be well adhered to skin and cannot stimulate skin; drug administration time is prolonged, the toxic and side effects on the whole body are reduced, the adaptability of patients is improved, and the propranolol hydrochloride lipidosome gel has excellent application prospect.

The invention relates to the field of fabric production, in particular to a breathable anti-abrasion anti-electrostatic and waterproof fabric and a preparing method thereof. The fabric is formed by blending cotton and linen fiber, viscosity fiber and anti-electrostatic polyester fiber; the fabric is prepared from, by weight, 30-40 parts of cotton and linen fiber, 35-40 parts of viscosity fiber, 30-40 parts of anti-electrostatic polyester fiber, 33-46 parts of polylactic acid, 25-38 parts of metasilicic acid trimethyl ester, 22-28 parts of dilauryl thiodipropionate, 21-25 parts of sodium dodecyl benzene sulfonate, 13-17 parts of phosphatidyl ethanolamine, 9-14 parts of potassium metabisulfite, 8-9 parts of cetyl trimethyl ammonium bromide, 8-9 parts of hydroxypropyl starches, 5-7 parts of nano silicon dioxide, 5-7 parts of sodium cetyl sulfate, 4-6 parts of linoleic acid, 3-4 parts of silane coupling agent, 3-4 parts of binding agent and 180 parts of deionized water.

The invention belongs to the field of medicine preparations, which particularly relates to a long-circulation irinotecan lipidosome composition. The long-circulation irinotecan lipidosome composition is prepared from the following components in parts by weight: 1 part of irinotecan, 2 to 4 parts of hydrogenated soy phosphatidylcholine or distearoyl lecithin, 0.5 to 1.5 parts of cholesterol, 0.4 to 1.2 parts of phosphatidylethanolamine pegol and 0.0104 to 0.051 part of metal-chelator. The invention further discloses a preparation method of the long-circulation irinotecan lipidosome composition and an application of the long-circulation irinotecan lipidosome composition prepared into an irinotecan lipidosome composition injection. According to the irinotecan lipidosome composition and the preparation method thereof, the medicine loading ratio of the irinotecan is greatly improved and the encapsulation efficiency is greater than 99.5%, so that the toxic and side effect of the medicine which is not encapsulated can be obviously reduced; the content of relevant substances is lower than 0.5% and the limit of various toxic impurities is lower than 0.1%, so that the safety of the composition is obviously improved; and the composition is uniform in granularity distribution and good in stability.

The invention discloses a meropenem liposome injection, which is characterized by mainly comprising the following components of: by weight, one part of meropenem, 2-8 parts of phosphatidylethanolamine, 1-5 parts of cholesterol, 0.2-1 part of polyether 188, 0.1-0.4 part of an antioxidant, and 5-10 parts of a supporting agent. The liposome injection prepared in the invention has good redissolving performance, good stability, high entrapment rate and little side-effect, can be used to raise the preparation product quality, minimize toxic and side effects and improve the bioavailability, and has remarkable curative effects.

The invention relates to a thermosensitive silica body and a preparing method and application thereof. The thermosensitive silica body and high-intensity focused ultrasound beams (HIFU) are combined and used for controlling release of hydrophobic drugs. The thermosensitive silica body is prepared from, by weight, 41.90-62.90 parts of lipid formed by the silica body, 40.00-60.00 parts of dipalmitoyl phosphatidyl choline, 5.20-8.50 parts of palmitoyl phosphatidyl choline and 14.00-19.50 parts of polyethylene glycol 2000-dipalmitoyl phosphatidyl ethanolamine. The thermosensitive silica body is high in stability and biocompatibility and capable of fast releasing the hydrophobic antineoplastic drugs when combined with HIFU and shows a remarkable therapeutic effect.

The invention discloses an application of a group of metabolic markers in early diagnosis of a metabolic syndrome. The metabolic markers at least comprise glutamine-leucine and phosphatidyl ethanolamine PE (18:2(9Z,12Z)/P-18:0), and further comprise tyrosine or phenylalanine. In a validation set of a specific embodiment, the accuracy degree for distinguishing a health volunteer and a metabolic syndrome patient through joint use of tyrosine, phosphatidyl ethanolamine PE (18:2(9Z,12Z)/P-18:0) and glutamine-leucine reaches 80.5%, and the accuracy degree for distinguishing the health volunteer andthe metabolic syndrome patient through joint use of phenylalanine, glutamine-leucine and phosphatidyl ethanolamine PE (18:2(9Z,12Z)/P-18:0)reaches 82.6%. Therefore, the abovementioned metabolic markers have high accuracy degree for diagnosis of the metabolic syndrome, can be prepared into a metabolic syndrome diagnosis kit and are used for early diagnosis of a healthy person suffering from the metabolic syndrome.

The invention relates to a method for quickly modifying avidin on an interface based on lipidosome. The method comprises the steps of mixing phospholipid and biotinylated phosphatidyl ethanol, adding chloroform for ultrasonic stirring, drying under nitrogen, and vacuum drying; adding a neutral solution, matching films with different bore diameters for a squeezer, and squeezing for multiple times so as to form lipidosomes with different sizes; after cleaning a glass slide, soaking in a hydrofluoric acid solution with the concentration being 1 percent for dozens of seconds, then washing with pure water, and drying under the nitrogen; putting the glass slide into a clean utensil, dropwise adding a certain amount of synthetic lipidosome, incubating for several minutes at the temperature higher than the phase-transition temperature, and using super-pure water for cleaning excessive lipidosome; later, adding the avidin for incubating for several minutes, using the super-pure water or solution to clean excessive avidin, and obtaining a glass interface with the avidin modified on the surface. The method is simple, convenient and quick in modification steps, uniform in modification, and complete in sealing, and since silanization reagents are not introduced during a modification process, the background interference is less. The prepared interface can meet the requirement on single molecule enzymology research.

The invention discloses an SPIO labeled pH sensitive drug-carrying liposome which is prepared from the following components in parts by mass: 1-10 parts of bulk drugs, 1-50 parts of phosphatidyl ethanolamine, 1-30 parts of cholesterol, 1-30 parts of linoleic acid, 0-10 parts of carboxymethyl chitosan, and 0-10 parts of superparamagnetic iron oxide nanoparticles. The invention further discloses a preparation method of the SPIO labeled pH sensitive drug-carrying liposome. The preparation method comprises the following steps: S1, placing phosphatidyl ethanolamine, cholesterol and linoleic acid ina flask, adding chloroform for dissolving, adding a water soluble drug solution for ultrasonic treatment to form a W/O emulsion; S2, evaporating to a gel state under the pressure reduction condition;adding a buffering solution, and continuously evaporating to form an aqueous suspension; S3, adding the superparamagnetic iron oxide nanoparticles and performing freeze thawing on a liposome suspension for three times; and centrifugally removing the superparamagnetic iron oxide nanoparticles and the water soluble drug not in the aqueous suspension; and S4, adding a carboxymethyl chitosan solutionfor hydration.

The invention relates to a long-acting lyophilized powder injection preparation of cisatracurium besilate. The long-acting lyophilized powder injection preparation of the cisatracurium besilate is prepared from the following components in parts by weight: 3-10 parts of cisatracurium besilate, 10-40 parts of polyethylene glycol-phosphatidyl ethanolamine, 10-30 parts of soya bean lecithin, 5-15 parts of sodium deoxycholate, 0.15-0.50 part of an antioxidant, 0.5-1 part of polyvinylpyrrolidone and 5-25 parts of a frozen-dried supporting agent. The preparation can be used for intravenous administration, the problem of the mass stability is effectively solved, the pharmacodynamic action time and the bioavailability of the preparation are improved, and meanwhile, the toxic or side effect is also relatively reduced.

The invention discloses an oxygen-carrying phospholipid microcapsule, a preparation method thereof and application of the oxygen-carrying phospholipid microcapsule in preparation of an anti-hypoxia drug, and the preparation method comprises the following steps: adding myristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, dipalmitoyl phosphatidylethanole-polyethylene glycol 2000-triphenyl phosphate and an organic solvent into a container, and carrying out ultrasonic treatment to obtain a clear solution; performing reduced pressure evaporation to remove the organic solvent, and adhering a layer of uniform and transparent faint yellow film on the inner wall of the container; carrying out vacuum drying, adding ultrapure water, hydrating in an ice bath to obtain phospholipid microcapsules, and putting the phospholipid microcapsules in the ice bath; adding perfluorohexane to obtain a mixed system, and performing ultrasonic dispersion until the mixed system is not layered to obtain an emulsion; and adding a freeze-drying protective agent, freeze-drying, storing at 4 DEG C, and redissolving and oxygenating before use to obtain the oxygen-carrying phospholipid microcapsule. The preparation method is simple and controllable, and raw materials and auxiliary materials are easy to obtain; the prepared oxygen-carrying phospholipid micro-capsule is uniform in particle size and good in stability and biocompatibility, oxygen can be supplemented to an organism in time, and the effect of treating diseases is achieved.

The invention provides a concrete additive which comprises the following components in parts by weight: 5-10 parts of polyurethane modified fly ash, 20-30 parts of indolyl sulfo diphenyl ketone polyphenyl ether, 10-15 parts of MPEG-2000-DSPE, 10-15 parts of pentaerythritol and 10-15 parts of deionized water. The invention also discloses a preparation method of the concrete additive. The preparation method of the concrete additive disclosed by the invention is simple and feasible, the raw materials are easy to obtain, the preparation cost is low, the dependence on equipment is small, and the method is suitable for large-scale production; the prepared concrete additive has various functions, is more obvious in improvement effect on the strength, fluidity, durability and impermeability of concrete, and has the advantages of being less in using amount and more excellent in comprehensive performance.

The invention belongs to the technical field of biology, and relates to a series of metabolites for diagnosis of subclinical pelvic inflammation disease. A metabonomic method based on liquid chromatogram-mass spectrometry is used for systematically screening metabolites in blood, in order to find metabolites which have obvious correlation to existence of generation of subclinical pelvic inflammation disease as biomarkers of the disease. The metabolites comprise the following components: lysobisphosphatidic acids 16:0/0:0, ceramide-1-phosphate d18:1/16:0, stearamide, linoleic acid, stearic acid, phosphatidylethanol P-18:0/0:0, phosphatidyl ethanolamine P-18:0/0:0, lysobisphosphatidyl ethanolamine P-20:0/0:0, indoxylsulfuric acid, 3-indolepropionic acid, and p-methylphenol. The biomarkers are used for noninvasive diagnosis and indication treatment of the subclinical pelvic inflammation disease, and compared with clinic methods for diagnosis by operation, the biomarkers have obvious advantages.

The invention discloses a pirarubicin freeze-dried preparation. The preparation is composed of the following components with the contents: 8 to 12g of pirarubicin or pirarubicin hydrochloride, 50 to 75g of hydrogenated soybean lecithin, 28 to 42g of cholesterol, 3 to 5g of PEG2000-1, 2-dipalmitoyl-glycero-3-phosphoethanolamine, 1.2 to 2g of poloxamer 188, 32 to 50mg of Alpha-tocopherol and 450 to900g of sucrose. The preparation has good anti-cancer function, small toxicity and high stability, and the target of the drug is improved simultaneously. The invention further discloses a preparationmethod of the pirarubicin freeze-dried preparation.

The invention relates to an ultrasonic contrast agent which comprises a shell material, gas and a 6% dextran injection solution. The shell material is prepared from, by weight, 10% of dipalmitoyl phosphatidylcholine, 5% of phosphatidyl ethanolamine, 10% of polyvinylpyrrolidone, 10% of polyethylene glycol monostearate, 15% of span 80, 15% of sodium alginate, 5% of sucrose ester and 30% of injection water. The gas is prepared from perfluoro-n-butane and sulfur hexafluoride at the volume ratio of 1:3. The ultrasonic contrast agent has the advantages of being long in stable time, good in using effect, long in circulation half-life period and simple in preparing method, and has very high clinical application value.

The invention provides a combined product for detecting enzyme activity of PEMT (phosphatidyl ethanolamine N-methyltransferase). The combined product contains S-adenosine-L-methionine or an enzyme reaction system capable of producing S-adenosine-L-methionine, a methyl receptor and S-adenosine-L-homocysteine hydrolase, wherein the enzyme reaction system capable of producing S-adenosine-L-methionine comprises adenosine triphosphate, methionine and S-adenosylmethionine. Preferably, the combined product adopts a kit form, and all components are in self-existent reagent states. The combined product can be used on semi-automatic or full-automatic analysis detection equipment and is high in detection sensitivity, high in specificity and convenient to operate, so that the combined product can be popularized and used actually.

The invention discloses a slow-release solid preparation of a doxycycline ambroxol medicine compound and a preparation method thereof. The preparation method comprises the following steps: preparing a vesica type phospholipid gel by adopting the following materials in parts by weight: 10 parts of doxycycline hydrochloride (count by doxycycline), 7 parts of ambroxol hydrochloride, 30-300 parts of distearoyl phosphatidylcholine ethanolamine and 10-100 parts of cholesterol succinate, and then adding frequently-used other medicinal excipients to the vesica type phospholipid gel of the doxycyclineambroxol medicine compound, thereby obtaining the slow-release solid preparation. According to the preparation method provided by the invention, the quality of preparation product is increased, the toxic side effect is reduced, the stability and dissolution rate as well as bioavailability of the medicine are greatly increased, the effect is stable and long-lasting, and the curative effect is obvious.